We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+32.54%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$343M
AUM Growth
+$158M
Cap. Flow
+$103M
Cap. Flow %
29.91%
Top 10 Hldgs %
65.57%
Holding
72
New
18
Increased
24
Reduced
6
Closed
20

Top Buys

Rank Stock Value
1
NUVA
NuVasive, Inc.
NUVA
+$17.6M
2
AMRN
Amarin Corp
AMRN
+$14.4M
3
DHR icon
Danaher
DHR
+$12.8M
4
EHTH icon
eHealth
EHTH
+$11.1M
5
GSK icon
GSK
GSK
+$10.9M

Top Sells

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$5.19M
2
MRK icon
Merck
MRK
+$3.53M
3
ZGNX
Zogenix, Inc.
ZGNX
+$3.24M
4
TSRO
TESARO, Inc.
TSRO
+$2.67M
5
ABT icon
Abbott
ABT
+$2.27M

Sector Composition

Rank Sector Weight
1 Healthcare 86.25%
2 Industrials 8.36%
3 Financials 3.65%
4 Miscellaneous 1.46%
5 Real Estate 0.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TLGT
26
DELISTED
Teligent, Inc
TLGT
$2.99M 0.87%
257,488
+32,740
+15% +$494K
IRWD icon
27
Ironwood Pharmaceuticals
IRWD
$682M
$2.65M 0.77%
+233,667
New +$2.61M
DERM
28
DELISTED
Dermira, Inc.
DERM
$2.43M 0.71%
+179,500
New +$1.5M
XENE icon
29
Xenon Pharmaceuticals
XENE
$5.81B
$2.28M 0.66%
224,340
+19,236
+9% +$163K
MDCO
30
DELISTED
Medicines Co
MDCO
$2.13M 0.62%
+76,200
New +$1.8M
APLS
31
DELISTED
Apellis Pharmaceuticals
APLS
$2.03M 0.59%
104,349
-2,531
-2% -$39.8K
TCDA
32
DELISTED
Tricida, Inc. Common Stock
TCDA
$1.91M 0.56%
49,508
+8,986
+22% +$209K
MYOK
33
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$1.82M 0.53%
+35,052
New +$1.61M
CHRS icon
34
Coherus Oncology
CHRS
$218M
$1.64M 0.48%
+120,036
New +$1.6M
CRSP icon
35
CRISPR Therapeutics
CRSP
$5.58B
$1.51M 0.44%
+42,400
New +$1.47M
CBAY
36
DELISTED
Cymabay Therapeutics
CBAY
$1.42M 0.42%
107,296
+60,200
+128% +$640K
AFMD
37
DELISTED
Affimed
AFMD
$1.35M 0.39%
32,217
-1,360
-4% -$48.9K
CNC icon
38
Centene
CNC
$32B
$1.25M 0.37%
23,600
+15,000
+174% +$911K
FOMX
39
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$1.1M 0.32%
294,660
– –
CTRE icon
40
CareTrust REIT
CTRE
$9.22B
$977K 0.28%
41,264
-10,000
-20% -$219K
EIGR
41
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$975K 0.28%
+2,324
New +$933K
IVC
42
DELISTED
Invacare Corporation
IVC
$662K 0.19%
79,081
+5,179
+7% +$37.3K
DRNA
43
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$602K 0.18%
41,074
– –
ALBO
44
DELISTED
Albireo Pharma Inc
ALBO
$581K 0.17%
18,029
– –
CNCE
45
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$569K 0.17%
+47,154
New +$695K
HSKA
46
DELISTED
Heska Corp
HSKA
$569K 0.17%
+6,680
New +$602K
OTIC
47
DELISTED
Otonomy, Inc.
OTIC
$474K 0.14%
+180,100
New +$406K
PFNX
48
DELISTED
Pfenex Inc.
PFNX
$468K 0.14%
+75,700
New +$331K
OPCH icon
49
Option Care Health
OPCH
$3.58B
$246K 0.07%
+30,753
New +$404K
NGNE icon
50
Neurogene
NGNE
$732M
$199K 0.06%
3,686
– –
1
2
3

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q1 2019 Portfolio in Review

As of Q1 2019, Eversept Partners held 72 positions worth $343M, up 86% from $185M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Eversept Partners deployed $103M of net new capital in Q1 2019, opening 18 new positions and adding to 24 existing holdings. Its largest new stake was NuVasive, Inc.: 330,601 shares worth $18.8M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 87% a quarter earlier, followed by Industrials and Financials.

On the sell side, the largest reduction was Aerie Pharmaceuticals, an estimated $5.19M trimmed.

  • Eversept Partners's largest Q1 2019 buy was NuVasive, Inc.: 330,601 shares worth $18.8M.
  • Eversept Partners added most to Amarin Corp in Q1 2019, an estimated $14.4M increase.
  • Eversept Partners's biggest Q1 2019 reduction was Aerie Pharmaceuticals, cutting an estimated $5.19M.
  • Eversept Partners fully exited Merck in Q1 2019, selling an estimated $3.53M.
  • Eversept Partners's ten largest holdings make up 66% of its $343M portfolio in Q1 2019.
  • Eversept Partners opened 18 new positions and closed 20 in Q1 2019.
  • Eversept Partners's portfolio value rose 86% quarter-over-quarter to $343M.

Based on Eversept Partners's 13F filing for Q1 2019, filed 14 May 2019.